In less than a decade, the resources available to treat light chain (AL) amyloidosis have increased impressively.
Giampaolo Merlini, MD
Advertisement
Articles by Giampaolo Merlini, MD
Advertisement
Latest Updated Articles
- Uniform Risk-Stratification and Response Criteria Are Paving the Way to Evidence-Based Treatment of AL Amyloidosis
Published: June 15th 2011 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
Frontline Alectinib Upholds OS Benefit in Advanced ALK+ NSCLC
2
Episode 16: Anticipated ESMO 2025 Data That May Change GU Oncology
3
Osimertinib/Chemo Yields OS Improvement Across Subgroups of EGFR+ NSCLC
4
Perioperative Durvalumab/NAT Chemo Does Not Improve HRQOL in MIBC
5
